Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
Chaïma Cherif, Dang Tan Nguyen, Clément Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthélémy, Daniel Birnbaum, François Bertucci, David Taïeb
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProstate Cancer Treatment and Research · S100 Proteins and Annexins · Prostate Cancer Diagnosis and Treatment
Correction to: Oncogene 10.1038/s41388-021-02039-2, published online 28 October 2021
In the original version, details about the animal ethics approval were not mentioned in the section ‘Assessment of in vivo tumor growth’. Accordingly the text passage now reads as follows:
‘P. Rocchi who supervised the animal experiments, obtained permission for animal experiments by ethical committee following European rules (APAFIS#26169-2020062314545490 v4, Direction générale de la recherche et de l’innovation (DGRI), 75231 Paris Cedex 05)’ instead of ‘Palma Rocchi possesses personal agreement (#A13-477) for the animal handling and experimentation for this study. Animal experimentation was carried out accordingly to ethics laws recommendations’.
Correction to: Competing Interests
In the original version, the ‘Competing Interest’ statement was incorrectly given as ‘The authors declare no competing interests’ but should have been ‘The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of Hsp27, listing PR and MG as inventors. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. PR and DT are cofounders of SilonTx ([Silon Therapeutics | Advancing Innovative Therapies | https://silontx.com/]), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics’.
The original article has been corrected.